Bradykinin release and inactivation in brain of rats submitted to an experimental model of Alzheimer's disease

Peptides. 2006 Dec;27(12):3363-9. doi: 10.1016/j.peptides.2006.08.012. Epub 2006 Oct 9.

Abstract

The kallikrein-kinin system is involved in a variety of physiological and pathological processes. Components of this system, identified in rat and human brains, can be altered in neurodegenerative processes such as Alzheimer's disease. Here, we studied kinin release and its inactivation in rats submitted to chronic cerebroventricular infusion of beta-amyloid (Abeta) peptide. Neurodegeneration was confirmed by histological analysis of brain samples. In cerebrospinal fluid of animals infused with Abeta, bradykinin concentration was increased, as determined by radioimmunoassay. However, in the brain of Abeta group, we only detected the tripeptide Arg-Pro-Pro, purified by reversed-phase chromatography and characterized by liquid chromatography-electrospray ionization mass spectrometry. This fragment of bradykinin indicated the possible participation of kinin-processing enzymes in the brain such as a prolyl oligopeptidase.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / metabolism*
  • Animals
  • Bradykinin / antagonists & inhibitors*
  • Bradykinin / metabolism*
  • Brain / metabolism*
  • Disease Models, Animal
  • Rats

Substances

  • Bradykinin